LifeStance Health Group (NASDAQ:LFST) Director Sells $11,975.04 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 1,701 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.04, for a total value of $11,975.04. Following the completion of the transaction, the director owned 1,318,133 shares of the company’s stock, valued at approximately $9,279,656.32. This represents a 0.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Friday, December 19th, Robert Bessler sold 119,942 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68.
• On Thursday, December 18th, Robert Bessler sold 6,442 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $45,094.00.
• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total transaction of $558,206.30.

LifeStance Health Group Price Performance

Shares of LFST traded up $0.01 during mid-day trading on Tuesday, reaching $7.06. 1,276,911 shares of the stock traded hands, compared to its average volume of 2,381,689. The company has a market cap of $2.75 billion, a price-to-earnings ratio of -235.33 and a beta of 1.13. LifeStance Health Group, Inc. has a 1 year low of $3.74 and a 1 year high of $8.30. The firm has a fifty day moving average price of $6.07 and a 200 day moving average price of $5.38. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. During the same quarter last year, the company earned ($0.02) earnings per share. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. As a group, equities research analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its position in shares of LifeStance Health Group by 1.4% in the first quarter. Invesco Ltd. now owns 164,384 shares of the company’s stock valued at $1,095,000 after acquiring an additional 2,238 shares during the period. Vident Advisory LLC grew its stake in shares of LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after purchasing an additional 2,447 shares during the last quarter. State of Wyoming increased its holdings in LifeStance Health Group by 3.8% during the 3rd quarter. State of Wyoming now owns 89,927 shares of the company’s stock valued at $495,000 after purchasing an additional 3,298 shares during the period. Legal & General Group Plc lifted its holdings in LifeStance Health Group by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock worth $746,000 after buying an additional 3,331 shares during the period. Finally, Polar Capital Holdings Plc grew its position in shares of LifeStance Health Group by 19.3% in the 3rd quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company’s stock worth $120,000 after buying an additional 3,525 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LFST shares. UBS Group lifted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Wall Street Zen cut LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday. Finally, Barclays assumed coverage on LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.83.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.